Executive Director of Biostatistics (Inflammation) at Gilead Sciences

Foster City, California, United States

Gilead Sciences Logo
Not SpecifiedCompensation
Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, BiotechnologyIndustries

Requirements

  • Excellent verbal and written communication skills
  • Excellent negotiation and interpersonal skills
  • In depth knowledge of the drug development process
  • In depth knowledge of and strong advocate for Good Clinical Trial Practices, ICH, and regulatory guidance
  • Proven ability to supervise team leads who supervise personnel
  • Ability to delegate, coach, and provide feedback and career development opportunities to team-members
  • Ability to provide team-members with a framework for decision-making that delineates the actions associated

Responsibilities

  • Provides statistical oversight of all biostatisticians in the TA and all biostatistics-related work conducted by internal biostatisticians and external consultants for the TA
  • Provides strategic inputs and statistical expertise for clinical development programs. Partners and collaborates with cross-functional TA leads to meet the regulatory, scientific and business objectives
  • Oversees and contributes to the completion of all technical and operational statistical activities in the TA through management of internal and external resources
  • Anticipates emerging projects in the TA and works with senior management to develop staffing plan. Properly assigns and manages resource according to priorities and development strategies
  • Negotiates project timelines across programs with competing priorities given constraints. Manages and coordinates limited resources to produce quality deliverables within timelines
  • Ensures adherence to SOPs, BEDs, and all departmental standards and processes regarding the conduct of clinical trials, statistical methodology, data analysis and interpretation
  • Champions the development and training of decision-enabled statistical tools. Explores opportunities for more efficient and innovative statistical approaches
  • Responsible for ensuring scientific integrity of the statistical methodology applied to clinical trials. Accountable for ensuring rigorous statistical approaches implemented in the TA
  • Encourages and empowers biostatisticians to exercise good judgement, embrace data-driven approach, and follow the best practices and principles to become accountable decision-makers

Skills

Biostatistics
Clinical Trials
Regulatory Submissions
Statistical Analysis
People Leadership
Functional Leadership
Therapeutic Area Management

Gilead Sciences

Develops and commercializes biopharmaceuticals

About Gilead Sciences

Gilead Sciences focuses on discovering, developing, and commercializing medicines for various medical conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company conducts extensive research and development to create new therapies, which are then marketed to healthcare providers, hospitals, and pharmacies after receiving regulatory approval. Gilead differentiates itself from competitors through its strong commitment to R&D and strategic partnerships, such as with SAP Ariba, to enhance its operations and product offerings. The company's goal is to improve health equity and access to care globally, working with communities to ensure that its medicines reach those in need.

Foster City, CaliforniaHeadquarters
1987Year Founded
$15,873.6MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Benefits

Paid family time off and paid parental time off
Generous 401(k) contribution matching
Comprehensive medical plans that cover both physical and mental healthcare
Global Wellbeing Reimbursement
Time Off
Global Volunteer Day
Giving Together Program
Employee Support Programs
Flexible Work Options

Risks

Increased competition in HIV treatment from ViiV Healthcare's expanding drug portfolio.
Regulatory scrutiny over drug pricing could impact Gilead's U.S. market operations.
Patent expirations, like Truvada's, lead to increased generic competition and revenue loss.

Differentiation

Gilead's lenacapavir is recognized as the 2024 Breakthrough of the Year for HIV care.
Partnerships with LEO Pharma and Tubulis enhance Gilead's focus on inflammatory and cancer therapies.
Gilead's commitment to health equity initiatives like COMPASS and HepConnect sets it apart.

Upsides

Gilead's strategic partnerships expand its reach in inflammatory and oncology drug markets.
Investment in digital health technologies enhances Gilead's R&D and patient engagement.
Focus on sustainability improves Gilead's operational efficiency and corporate reputation.

Land your dream remote job 3x faster with AI